Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03737448
Other study ID # MP-0614-001
Secondary ID
Status Suspended
Phase Phase 1
First received
Last updated
Start date November 28, 2018
Est. completion date June 30, 2021

Study information

Verified date March 2021
Source Martin Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.


Description:

The study will assess the PK, tolerability, and safety of oral trimetazidine administered to subjects with acute-on-chronic (ACLF) Grades 1 and 2 with liver failure and a range of renal function. Subjects will receive up to 60 mg/day for 28 days. Two groups of subjects will be enrolled: Group 1 - AD with serum creatinine ≥ 1 and < 2 mg/dL, OR - ACLF 1 with - liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or - liver failure and West Haven grade 1-2 hepatic encephalopathy, or - coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or - coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR - ACLF 2 with - liver failure and coagulation failure, or - liver failure and West Haven grade 3-4 hepatic encephalopathy. Group 2 - ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR - ACLF 2 with - liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or - coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL).


Recruitment information / eligibility

Status Suspended
Enrollment 30
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18 to 75 years, inclusive, at screening. 2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as determined at the discretion of the investigator)*. 3. Anticipated duration of hospital stay of at least 7 days. 4. For Group 1: - AD with SCr = 1 and < 2 mg/dL, OR - ACLF 1 with - Tbil = 12 mg/dL, SCr = 1.5 and < 2 mg/dl, and HE 0-2, or - Tbil = 12 mg/dL, and SCr < 1.5 mg/dL, and HE 1-2, or - INR = 2.5, SCr = 1.5 and < 2 mg/dl, and HE 0-2, or - INR = 2.5, SCr < 1.5 mg/dL, and HE 1-2, OR - ACLF 2 with - Tbil = 12 mg/dL, INR = 2.5, and SCr < 2 mg/dL, or - Tbil = 12 mg/dL, HE 3-4, and SCr < 2 mg/dL 5. For Group 2: - ACLF 1 with SCr = 2.0 and < 3.5 mg/dL, OR - ACLF 2 with - Tbil = 12 mg/dL, and SCr = 2 and < 3.5 mg/dL, or - INR = 2.5, and SCr = 2 and < 3.5 mg/dL. 6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose. 7. Non sterile male patients must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose if sexually active. 8. Able to comprehend and willing to sign an informed consent form, or, if unable to consent, consent is conducted per local requirements. Exclusion Criteria: 1. Diagnosis of AD or ACLF (of any grade) >14 days before enrollment*. 2. Circulatory failure. 3. Respiratory failure i.e. PaO2/FiO2 = 200 and/or baseline SpO2/FiO2 = 214. 4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation failure (INR > 2.5). 5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this criterion may qualify after 72 hours). 6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at the discretion of the investigator). 7. Invasive fungal infection. 8. Platelet count <30,000 cells/mL. 9. White blood cell count <1000 cells/uL. 10. Patients on hemodialysis or continuous venovenous hemofiltration. 11. Patients who have undergone or are scheduled for imminent organ transplantation. (Patients may be on a transplant list as long as no date has been set for transplantation) 12. Hospitalization for ACLF within the 3 months prior to screening. 13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions each < 3 cm or 1 lesion < 5 cm; no extrahepatic involvement; no evidence of gross vascular invasion). 14. Active non-hepatic malignancy. 15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.), restless leg syndrome or other movement disorders other than asterixis. 16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome. 17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (> 18 mg/dL) after adequate fluid resuscitation. 18. Patients who have undergone placement of a transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt in the past 6 months. 19. Any invasive procedure within 48 hours prior to enrollment with high risk of uncontrolled bleeding (as determined at the discretion of the investigator). 20. Female with a positive pregnancy test or lactating. 21. Positive results for human immunodeficiency virus HIV-1 or HIV-2. 22. Current treatment with trimetazidine. 23. Known allergy to trimetazidine or excipients. 24. Currently receiving an investigational treatment. 25. Any condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study.

Study Design


Intervention

Drug:
Trimetazidine
Subjects with receive up to 60 mg daily

Locations

Country Name City State
Austria Medical University of Graz Graz
Austria Medical University of Innsbruck Innsbruck
Austria Medical University of Vienna Vienna
Belgium University of Antwerp Antwerp
Belgium Erasme Hospital Brussels
France Hospital Claude Huriez Lille
France Hospital Pitie-Salpetriere Paris
France Rennes University Hospital Rennes
France Hôpital Paul Brousse Villejuif
Germany University of Essen Essen
Germany JW Goethe Clinic Frankfurt
Germany Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin I Halle
Germany University of Hannover Hannover
Germany University of Heidelberg Heidelberg
Germany University of Leipzig Leipzig
Germany University of Münster Münster
Spain Hospital Clinic Barcelona
Spain Hospital Valle de Hebron Barcelona
Spain Hospital Reina Sofia Córdoba
Spain Hospital Gregorio Marañón Madrid
Spain Hospital Puerta de Hierro Madrid
Spain Hospital Ramon y Cajal Madrid
Spain Hospital Marques de Valdecilla Santander Santander
Spain Hospital Virgen del Rocio Seville

Sponsors (1)

Lead Sponsor Collaborator
Martin Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Belgium,  France,  Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary plasma pharmacokinetics Cmax 28 days
Primary plasma pharmacokinetics AUC 28 days
Secondary Incidence of treatment-emergent adverse events [Safety and Tolerability] Adverse events 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05985863 - Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT04822922 - Safety of UC-MSC Transfusion for ACLF Patients Phase 2
Recruiting NCT04578301 - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Completed NCT04983108 - Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT05036031 - Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Recruiting NCT05019352 - Cytokine Adsorption in Acute-on-chronic Liver Failure N/A
Recruiting NCT05421351 - Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
Completed NCT02321371 - Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy. N/A
Not yet recruiting NCT06069037 - SALT for Treatment of Patients With Early ACLF N/A
Completed NCT02965560 - Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Recruiting NCT03713489 - Platelet Transfusion in HBV-related acute-on Chronic Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Recruiting NCT04157465 - Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients N/A
Recruiting NCT06128421 - Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk N/A
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT04238416 - Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF Phase 1
Completed NCT03456518 - Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease
Recruiting NCT03987893 - PEG3350 in ACLF With Hepatic Encephalopathy Phase 4